Clinical Features and Outcomes of Diffuse Large B-cell Lymphoma Based on Nodal or Extranodal Primary Sites of Origin: Analysis of 1,085 WHO Classified Cases in a Single Institution in China
Overview
Authors
Affiliations
Objective: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma (DLBCL) patients in China according to the primary site.
Methods: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site.
Results: In the 1,085 patients, 679 (62.6%) cases were nodal DLBCL (N-DLBCL) and 406 cases (37.4%) were extranodal DLBCL (EN-DLBCL). The most common sites of N-DLBCL were lymphonodus (64.8%), Waldeyer's ring (19.7%), mediastinum (12.8%) and spleen (2.7%), while in EN-DLBCL, stomach (22.4%), intestine (16.0%), nose and sinuses (8.9%), testis (8.4%), skin (7.9%), thyroid (6.9%), central nervous system (CNS) (6.4%), breast (5.7%), bone (3.4%), and salivary gland (2.7%) were most common. N-DLBCL patients tend to present B symptoms, bulky disease, and elevated LDH more often, while age >60 years, extranodal sites >1, Ann Arbor stage I or II, bone marrow involvement, and Ki-67 index >90% were usually seen in EN-DLBCL. The 5-year overall survival (OS) rate and progression-free survival (PFS) rate for all patients were 62.5% and 54.2%. The 5-year OS rate for patients with N-DLBCL and EN-DLBCL were 65.5% and 56.9% (P=0.008), and the 5-year PFS were 57.0% and 49.0% (P=0.020). Waldeyer's ring originated DLBCL possessed the highest 5-year OS rate (83.6%) and PFS rate (76.9%) in N-DLBCL. The top five EN-DLBCL subtypes with favorable prognosis were stomach, breast, nose and sinuses, lung, salivary gland, with 5-year OS rate: 70.3%, 69.6%, 69.4%, 66.7% and 63.6%, respectively. While CNS, testis, oral cavity and kidney originated EN-DLBCL faced miserable prognosis, with 5-year OS rate of 26.9%, 38.2%, and 42.9%.
Conclusions: In our study, primary sites were associated with clinical characteristics and outcomes. Compared with EN-DLBCL, N-DLBCL had better prognosis.
Alharbi I, Salawati F, Alnajjar S, Alabbasi A J Med Cases. 2024; 15(11):324-329.
PMID: 39421222 PMC: 11483147. DOI: 10.14740/jmc4288.
Clinical and Biomarker Characteristic of Lymphoma Patients in Hasan Sadikin Lymphoma Registry.
Oehadian A, Kartikasari A, Mersiana L, Gunadi S, Fungani G, Vidyaniati P J Blood Med. 2024; 15:341-349.
PMID: 39132284 PMC: 11314504. DOI: 10.2147/JBM.S472791.
Yonghao O, Yongyang W, Siqing Y, Chengchao F, Lihua C, Xin L Indian J Hematol Blood Transfus. 2024; 40(2):220-230.
PMID: 38708154 PMC: 11065835. DOI: 10.1007/s12288-023-01706-6.
Tang C, Jiang P, Tang J, Liao J, Zeng Q Heliyon. 2024; 10(7):e28552.
PMID: 38560176 PMC: 10981111. DOI: 10.1016/j.heliyon.2024.e28552.
Qin Y, Song Y, Wang D, Bai O, Feng J, Sun X BMC Cancer. 2024; 24(1):124.
PMID: 38267866 PMC: 10809427. DOI: 10.1186/s12885-024-11876-9.